Filing Information

Inventor(s)	Matthias Zeis ·
Assignee(s)	Immatics Biotechnologies GmbH ·  View assignee updates
Correspondent	WOMBLE CARLYLE SANDRIDGE & RICE, PLLC ·
Application Number	US11912668
Filing date	04/26/2006
PCT 371 date	01/18/2008
Publication date	02/12/2009
Predicted expiration date	04/26/2026
U.S. Classifications	424/185.1  · 536/235  · 530/326  · 530/325  · 530/324  · 530/327  · 435/320.1  · 435/691  · 514/15  · 435/372.3  · 530/328  ·
International Classifications	A61K3808  · A61K3900  · C07K1447  · C07K706  · C07K708  · C12N1563  · C12N508  · C12P2102  ·
Kind Code	A1
PCT Application Number	WO20PCTEP2006003888 - 04/26/2006
Foreign Priority	EP05009095.0 - 04/26/2005 ·

Patent Family

Abstract

The present invention relates to the immunotherapB of cancer, in particular several tumor entities including hematological malignancies. The present invention relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class I or II molecules of human oncofoetal antigen immature laminin receptor (OFA/iLR), which can be used in vaccine compositions for eliciting anti-tumor immune responses.

Independent Claims | See all claims (33)

1. 1. A tumor associated peptide comprising at least one peptide set forth in SEQ ID NO: 1 or SEQ ID NO: 2 provided that the peptide is not the intact human tumor associated polypeptide and wherein the peptide has the ability to bind to the human major histocompatibility complex (MHC) class-I HLA-A*0201 molecule.
2. 5. (canceled)
3. 8. (canceled)
4. 11. (canceled)
5. 16. (canceled)
6. 18. (canceled)
7. 22.-23. (canceled)
8. 28. (canceled)
9. 33. A tumor associated peptide that has the ability to bind to the human major histocompatibility complex (MHC) class-I HLA-A*0201 molecule and also bind to a human major histocompatibility complex (MHC) class-II molecule HLA-DRB1 molecule selected from the group consisting of *0101, *0301, *0401, *0701, *1501, wherein the peptide comprises the following motif: B1-B2-B3-X1-B4-B5-X2-B6-X3-B7-B8-X4-B9-B10-B11 and wherein if the HLA-DRB1 is *0101, then B1, B2, B3, B4, B5, B6, B7, B8, B9, B10 and B11 is any amino acid; X1 is E, K, V, L, or W; X2 is L, E or A; X3 is A, P, or L; and X4 is A, I, V, or R; and wherein if the HLA-DRB1 is *0301, then B1, B2, B3, B4, B5, B6, B7, B8, B9, B10 and B11 is any amino acid; X1 is L, I, or K; X2 is A, I or W; X3 is R, N, or K; and X4 is V, D or R; and wherein if the HLA-DRB1 is *0401, then B1, B2, B3, B4, B5, B6, B8, B9, B10 and B11 is any amino acid; B7 is A, I, or P X1 is L, I, or V; X2 is A, I or E; X3 is R, A, N or P; and X4 is V, D or A; and wherein if the HLA-DRB1 is *0701, then B1, B2, B3, B4, B5, B6, B7, B8, B9, B10 and B11 is any amino acid; X1 is L or I; X2 is A or I; X3 is R, N or A; and X4 is V, D or A; and wherein if the HLA-DRB1 is *1501, then B1, B2, B3, B4, B5, B6, B8, B9, B10, B11 and X4 is any amino acid; B7 is I, L, V or A X1 is L, K or V; X2 is A, W, R, or E; and X3 is R, A, N or P.
10. 34. A tumor associated peptide that has the ability to bind to the human major histocompatibility complex (MHC) class-I HLA-A*0201 molecule and also bind to a human major histocompatibility complex (MHC) class-II molecule HLA-DRB1 molecule selected from the group consisting of *0101, *0301, *0401, *0701, *1501, wherein the peptide comprises the following motif: B1-B2-B3-X1-B4-B5-X2-B6-X3-B7-B8-X4-B9-B10-B11 and wherein if the HLA-DRB1 is *0101, then B1, B2, B3, B4, B5, B6, B7, B8, B9, B10 and B11 is any amino acid; X1 is Y or I; X2 is L or C; X3 is T; and X4 is L or P; and wherein if the HLA-DRB1 is *0301, then B1, B2, B3, B4, B5, B6, B7, B8, B9, B10 and B11 is any amino acid; X1 is C; X2 is D; X3 is P; and X4 is Y; and wherein if the HLA-DRB1 is *0401, then B1, B2, B3, B4, B6, B6, B8, B9, B10 and B11 is any amino acid; B7 is I, C or T X1 is Y, L or T; X2 is L or I; X3 is T, L or N; and X4 is L, T or S, and wherein if the HLA-DRB1 is *0701, then B1, B2, B3, B4, B5, B6, B7, B8, B9, B10 and B11 is any amino acid; X1 is Y or L; X2 is L or T; X3 is T or S; and X4 is L or R; and wherein if the HLA-DRB1 is *1501, then B1, B2, B3, B4, B5, B6, B8, B9, B10, B11 and X4 is any amino acid; B7 is I, D or P X1 is P, I or L; X2 is Y, C or T; and X3 is R, A, N or P.